drugset / Trial / NCT01928524
Chemotherapy for Patients With Cancer of the Stomach
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine maximal tolerable dose (MTD) of the combination of docetaxel, oxaliplatin and S1 (DOS) to patients with gastric cancer.
Timeline
- Start
- 2013-09
- Primary completion
- 2015-06-05
- Completion
- 2015-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DOS2w Dose level 1A | Unknown | 50 mg | — |
| Subject | DOS2w Dose level 1A | Unknown | 60 mg | — |
| Subject | DOS2w Dose level 1A | Unknown | 70 mg | — |
| Subject | Docetaxel | Small molecule | 30 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 40 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 50 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 70 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | — |